Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Control of Moderate or Severe Asthma With 160, 320 and 640 mcg Ciclesonide/Day. A One-year Randomised, Double-blind, Multicenter Trial.

NCT01455194 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01455194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01455194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Control of Moderate or Severe Asthma With 160, 320 and 640 mcg Ciclesonide/Day. A One-year Randomised, Double-blind, Multicenter Trial.
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2011
Completion date
August 31, 2014
Enrollment
520 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

bronchial asthma